{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transfusion+Dependent+Beta-Thalassaemia&page=2",
    "query": {
      "condition": "Transfusion Dependent Beta-Thalassaemia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transfusion+Dependent+Beta-Thalassaemia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:11:35.566Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04054921",
      "title": "Safety Study for Beta Thalassemia Subjects on PTG-300",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "β-thalassemia",
        "Ineffective Erythropoiesis"
      ],
      "interventions": [
        {
          "name": "PTG-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Protagonist Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-05-10",
      "completion_date": "2020-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04054921"
    },
    {
      "nct_id": "NCT01962415",
      "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions",
        "Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "Juvenile Rheumatoid Arthritis (JRA)"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "2 Months to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-02-04",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962415"
    },
    {
      "nct_id": "NCT03381833",
      "title": "A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "LJPC-401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "La Jolla Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2017-11-30",
      "completion_date": "2020-01-14",
      "has_results": false,
      "last_update_posted_date": "2021-07-29",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 2,
      "location_summary": "Oakland, California • New York, New York",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03381833"
    },
    {
      "nct_id": "NCT05145062",
      "title": "Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blood and Lymphatic Diseases"
      ],
      "interventions": [
        {
          "name": "BIVV003",
          "type": "DRUG"
        },
        {
          "name": "ST-400",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-12-21",
      "completion_date": "2038-07-14",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 7,
      "location_summary": "Oakland, California • Sacramento, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05145062"
    },
    {
      "nct_id": "NCT06647979",
      "title": "Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)",
        "Beta-Thalassemia",
        "Transfusion Dependent Beta-Thalassaemia"
      ],
      "interventions": [
        {
          "name": "autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sequencing Assay for Variant rs114518452",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Daniel Bauer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "13 Years to 40 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-12-01",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06647979"
    },
    {
      "nct_id": "NCT04770753",
      "title": "A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Transfusion-dependent Alpha-Thalassemia",
        "Non-Transfusion-dependent Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Placebo Matching Mitapivat",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2021-12-20",
      "completion_date": "2028-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770753"
    },
    {
      "nct_id": "NCT02274233",
      "title": "Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Iron Overload",
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "SP-420",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sideris Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-10",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2015-09-29",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02274233"
    },
    {
      "nct_id": "NCT02633943",
      "title": "Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transfusion-dependent Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 66,
      "start_date": "2014-01",
      "completion_date": "2035-11",
      "has_results": false,
      "last_update_posted_date": "2025-04-09",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 6,
      "location_summary": "Oakland, California • Chicago, Illinois • Bethesda, Maryland + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633943"
    },
    {
      "nct_id": "NCT06363760",
      "title": "A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease",
        "Transfusion-dependent Beta-Thalassemia",
        "Hemoglobinopathies"
      ],
      "interventions": [
        {
          "name": "Safety and efficacy assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Editas Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2024-06-17",
      "completion_date": "2040-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 16,
      "location_summary": "Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06363760"
    },
    {
      "nct_id": "NCT03655678",
      "title": "A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Beta-Thalassemia",
        "Thalassemia",
        "Genetic Diseases, Inborn",
        "Hematologic Diseases",
        "Hemoglobinopathies"
      ],
      "interventions": [
        {
          "name": "CTX001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 59,
      "start_date": "2018-09-14",
      "completion_date": "2025-11-13",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-05-22T09:11:35.566Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Chicago, Illinois • New York, New York + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03655678"
    }
  ]
}